News Ipsen to buy rare disease firm Clementia for up to $1.31bn France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to $1.31 billion.
News Daiichi and AZ pull Dato-DXd filing in Europe too AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
